Corbus Pharmaceuticals Holdings (LTS:0SZI) Stock Based Compensation: $6.49 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0SZI Corbus Pharmaceuticals Holdings Inc LTS:0SZI
37 GF Score
Price $8.95
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings Stock Based Compensation?

Corbus Pharmaceuticals Holdings LTS:0SZI +0.11% 37 Stock Based Compensation is $6.49 Mil as of Mar. 2026. GuruFocus rates LTS:0SZI with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

Corbus Pharmaceuticals Holdings's Stock Based Compensation for the three months ended in Mar. 2026 was $1.92 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $6.49 Mil.

Corbus Pharmaceuticals Holdings Stock Based Compensation Related Terms

Corbus Pharmaceuticals Holdings Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings Stock Based Compensation Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.48 5.72 3.47 6.15 6.29

Corbus Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.71 1.56 1.58 1.43 1.92
LTS:0SZI
37GF Score
Corbus Pharmaceuticals Holdings Inc LTS:0SZI
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.49 Mil.

What does a Stock Based Compensation of $6.49 Mil mean?
Corbus Pharmaceuticals Holdings (LTS:0SZI) has a Stock Based Compensation of $6.49 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Corbus Pharmaceuticals Holdings and its competitors.
Is Corbus Pharmaceuticals Holdings' Stock Based Compensation too high?
Corbus Pharmaceuticals Holdings' current Stock Based Compensation is $6.49 Mil. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Stock Based Compensation compare to PRQR and NRXP?
Corbus Pharmaceuticals Holdings' Stock Based Compensation of $6.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Corbus Pharmaceuticals Holdings and its competitors. Corbus Pharmaceuticals Holdings's current Stock Based Compensation is $6.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Corbus Pharmaceuticals Holdings (LTS:0SZI) has a current Stock Based Compensation of $6.49 Mil. The current Stock Based Compensation is $6.49 Mil. Corbus Pharmaceuticals Holdings' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (LTS:0SZI), the current Stock Based Compensation is $6.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA3371:Germany
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
37GF Score

Get the complete analysis for LTS:0SZI

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.95
Price